Sana Biotechnology appoints Dhaval Patel, M.D., CSO

Sana Biotechnology (SANA) announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. “We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future,” said Steve Harr, Sana’s President and Chief Executive Officer. Patel was previously Executive Vice President and Chief Scientific Officer at UCB, where he played a key role in its recent pipeline transformation. He and his teams contributed to the registration of Bimzelx( Rystiggo Zilbrysq . Prior to UCB, Dr. Patel spent 10 years at Novartis (NVS), most recently as the Head of Research of the Novartis Institutes for BioMedical Research NIBR Europe. During his tenure, he led research in autoimmune